当前位置: 首页 >> 检索结果
81. Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in LMNA Mutation-Induced Dilated Cardiomyopathy.
作者: Marie Kervella.;Charlotta S Behrens.;Cécile Peccate.;Zoheir Guesmia.;Fiorella Grandi.;Nathalie Mougenot.;Anne Forand.;Azzouz Charrabi.;Guy Brochier.;Ramaroson Andriantsitohaina.;Sonia R Singh.;Thomas Eschenhagen.;Albano C Meli.;Antoine Muchir.
来源: Circ Heart Fail. 2026年e013806页
Dilated cardiomyopathy caused by LMNA mutations is a severe cardiac condition marked by arrhythmias, contractile dysfunction, and excessive myocardial fibrosis, which collectively impair left ventricular function and increase the risk of heart failure. Although the disease has been well characterized, a lack of insight into the pathogenesis has impeded the development of therapies.
82. Letter by Ji and Benharrats Regarding Article "Artificial Intelligence-Enabled Echocardiography as a Surrogate for Multimodality Aortic Stenosis Imaging: Post Hoc Analysis of a Clinical Trial".84. CRLF1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy.
作者: Bowen Lin.;Jizheng Wang.;Can Li.;Shuiyun Wang.;Meiting Shen.;Lingjie Hu.;Lei Chen.;Fanhong Zhou.;Yiqiao Liu.;Jian Yang.;Mo Zhang.;Dong Wang.;Guoliang Xu.;Bin Zhou.;Lei Song.;Dan Shi.;Yi-Han Chen.
来源: Circulation. 2026年153卷11期845-862页
Hypertrophic cardiomyopathy (HCM), the most common inherited cardiac disorder and a leading cause of sudden cardiac death in young adults, exhibits substantial genetic and clinical heterogeneity. Although sarcomere gene sequence variations account for a major proportion of HCM cases, nearly half of patients lack identifiable genetic defects, implying the involvement of undiscovered mechanisms that may converge on a common pathogenic pathway. However, a unified molecular basis underlying HCM pathogenesis remains undefined.
86. Letter by Zou et al Regarding Article, "Impacts of Reducing Sitting Time or Increasing Sit-to-Stand Transitions on Blood Pressure and Glucose Regulation in Postmenopausal Women: Three-Arm Randomized Controlled Trial".87. Medication Costs for Dofetilide: Comparison of Insurance Copayments Versus Generic Pricing Through Cost Plus Drug Company.
作者: Godefroy Chery.;Amanda Every.;Andres Enriquez.;Rajat Deo.;Saman Nazarian.;David J Callans.;David S Frankel.;Francis E Marchlinski.;Timothy M Markman.
来源: Circulation. 2026年153卷11期868-870页 93. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
作者: .;Roger S Blumenthal.;Pamela B Morris.;Mario Gaudino.;Heather M Johnson.;Timothy S Anderson.;Vera A Bittner.;Ron Blankstein.;LaPrincess C Brewer.;Leslie Cho.;Sarah D de Ferranti.;Eugenia Gianos.;Ty J Gluckman.;Kristen F Gradney.;Ijeoma Isiadinso.;Donald M Lloyd-Jones.;Joel C Marrs.;Seth S Martin.;Kellie H McLain.;Laxmi S Mehta.;Samia Mora.;Wudeneh M Mulugeta.;Pradeep Natarajan.;Ann Marie Navar.;Carl E Orringer.;Tamar S Polonsky.;Harmony R Reynolds.;Joseph J Saseen.;Michael D Shapiro.;Daniel E Soffer.;Sheila A Tynes.;Chloé D Villavaso.;Salim S Virani.;John T Wilkins.; .
来源: Circulation. 2026年
The "2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia" retires and replaces the "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol."
94. The 2026 American College of Cardiology/American Heart Association Multisociety Guideline on the Management of Dyslipidemia: A More Precise-But More Complicated-Framework for Atherosclerotic Cardiovascular Disease Prevention and Treatment.96. Ruptured Left Sinus of Valsalva Aneurysm With Concomitant Aortic Stenosis Treated by TAVR: CT and TEE Findings.
作者: Yosuke Kirii.;Masaki Ishiyama.;Kosuke Kitada.;Akihiro Takasaki.;Taku Omori.;Emiyo Sugiura.;Tairo Kurita.;Takeo Takahashi.;Kaoru Dohi.
来源: Circ Cardiovasc Imaging. 2026年e019498页 97. Prospective Validation of the MIRACLE2 Score for Early Neurological Stratification After Out-of-Hospital Cardiac-Arrest: The GLOBAL-MIRACLE Registry.
作者: Muhamad Abd Razak.;George Vamvakas.;Michael McGarvey.;Samuel McGrath.;Krishnaraj Rathod.;Ahmed Elamin.;Zhihong Yao.;Peter Kordis.;Rupert Simpson.;Uzma Sajjad.;Zaid Iskandar.;Mandy Fish.;Garry Hamilton.;Piotr Pałczyński.;Szymon Tuchacz.;Arka Das.;Salaheldin Agamy.;Sundeep Kalra.;Abdul Mozid.;Rafal Dworakowski.;Mariusz Sieminksi.;Julian Yeoh.;Satpal Arri.;Thomas W Johnson.;Nick Curzen.;Marko Noc.;Clare Appleby.;Paul Rees.;Thomas R Keeble.;Ajay M Shah.;Philip MacCarthy.;Jonathan Byrne.;Daniel Stahl.;Nilesh Pareek.
来源: Circ Cardiovasc Interv. 2026年e015918页
The purpose of this study was to prospectively validate the MIRACLE2 score in the GLOBAL-MIRACLE registry, a multicenter, international, prospective registry of patients admitted with resuscitated out-of-hospital cardiac arrest of presumed cardiac cause.
|